Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. (Synergy) received marketing approval from the US Federal Drug Administration (FDA) for its first drug, Trulance, which targeted a large market that had only two other approved competitors. If you suffered a loss on your Synergy Pharmaceuticals Inc. After more than a decade of development, US-based Synergy Pharmaceuticals Inc. On this news, shares of Synergy fell significantly, thereby injuring investors. and one affiliated debtor (collectively, the Debtors) each filed a voluntary petition. Consequently, the loan was not available to Synergy "when needed," and would result in dilution of the outstanding shares, and would not be sufficient to fund operations through 2019, without dilution. On December 12, 2018, Synergy Pharmaceuticals Inc. On November 14, 2017, Synergy revealed the loan agreement terms, that was not previously disclosed, prevented the Company from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash, and therefore, Synergy was conducting a secondary offering of its shares. On September 5, 2017, Synergy revealed that it had closed on a "non-dilutive" $300 million loan from CRG Partners III L.P., which would be available to the Company "when needed" to fund its operations through 2019.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |